Paul A. Hamlin, MD

I specialize in the care of patients with Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL). I am a member of the Lymphoma Service in the Division of Hematologic Oncology, and I am board certified in internal medicine and medical oncology. My clinical research interests have focused on developing a treatment program for older patients with lymphoma and designing new strategies for treating HD and NHL through clinical research.

As part of a multidisciplinary team which cares for patients age 65 and older, I have worked to develop new treatment strategies for older patients with lymphoma. We have developed new screening tools to identify patients at potentially increased risk for treatment side effects and have developed clinical trials specifically aimed at addressing the needs of the older patient population. We have as our shared goal the development of effective risk-adapted therapies to minimize the side effects of treatments and maximize their effectiveness.

As a clinical researcher, I am exploring novel biologic and immunotherapeutic agents for the treatment of HD and NHL. My prior work focused on vaccine approaches for NHL and the use of radioimmunotherapy, with ongoing efforts exploring novel antibody therapies and antibody-drug combinations.